CardioFocus, Inc., a Markborough, MA-based medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), completed a $55m round of financing.
The company’s current syndicate of institutional investors participated in the financing, and included senior debt financing from Kennedy Lewis Investment Management.
The company intends to use the funds to accelerate the commercial introduction of the HeartLight Endoscopic Ablation System and global launch of the HeartLight X3 System, which received European CE Mark approval in March.
Led by Paul A. LaViolette, Executive Chairman, CardioFocus is a medical device innovator and manufacturer dedicated to advancing ablation treatment for cardiac disorders such as atrial fibrillation (AFib), the most common heart arrhythmia.
The company’s FDA-approved HeartLight Endoscopic Ablation System, a catheter ablation technology, has treated more than 6,500 patients in the United States, Europe and Japan.
The HeartLight X3 System is a third generation AFib ablation technology, building upon the advanced features of the HeartLight Endoscopic Ablation System, which performs PVI using laser energy to create lines of scar tissue to block the abnormal electrical pathways that cause AFib. Using direct tissue visualization, titratable laser energy, and compliant balloon technology, the system’s RAPID mode leverages a precise motor control system that enables uninterrupted, high-speed, circumferential lesion creation under direct control of the physician resulting in consistently reduced procedure times.
The HeartLight X3 System is only approved for use in Europe and is not available for sale in the U.S.